Stenotrophomonas maltophilia susceptibility testing challenges and strategies

Daniel D. Rhoads1 Pathology and Laboratory Medicine Institute,Cleveland,Clinic. Cleveland,Ohio.
DOI: https://doi.org/10.1128/JCM.01094-21
2021-07-01
Journal of Clinical Microbiology
Abstract:Stenotrophomonas maltophilia is intrinsically resistant to many beta lactam antibiotics including carbapenems and is resistant to aminoglycosides, which limits the therapeutic repertoire for managing S. maltophilia infections. Additionally, employing automated in vitro susceptibility testing of S. maltophilia is challenging because commercial test systems' performance is limited (A. Khan, C. A. Arias, A. Abbott, J. Dien Bard, et al., J Clin Microbiol 59:e00654-21, 2021, https://doi.org/10.1128/JCM.00654-21 ). This commentary will briefly discuss the opportunity to use automated commercial susceptibility testing systems with S. maltophilia with a focus on how to practically implement their use while mitigating risk of error.
microbiology
What problem does this paper attempt to address?